Here is some reading and background information concerning cancer and medical marijuana. Please note some of these may not be the latest information but are included to offer a wide range of sources and opinions, they do not constitute medical advice, and in almost every case more research is needed before there is certainty.
A new series of tests conducted in Israel have shown that both CBC and CBG exhibit anti-tumour properties on cancer cells. The test have been carried out by Cannabics Pharmaceuticals at the company’s High Through-put Screening (HTS) facility in Israel. The tests have shown that the cannabinoids CBC (Cannabichromene) and CBG (Cannabigerol) both exhibit anti-tumour properties after being tested on human Gastrointestinal Cancer Cells. CBC is an additional non-psychoactive cannabinoid and is one of the naturally occurring phyto-cannabinoids, bearing a host of potential positive therapeutic qualities and may promote antimicrobial, anti‐inflammatory, analgesic, and neurogenesis activity. It is particularly found in younger cannabis plants, albeit in small quantities. In these tests, the HTS platform was utilised to screen the necrotic effects of a variety of cannabinoids on human gastrointestinal cancer cells, in addition to other cancer types previously tested.
Read more here.